435 related articles for article (PubMed ID: 32571409)
1. Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-naïve patients.
Chen S; Han Y; Song XJ; Li YL; Zhu T; Lu HZ; Tang XP; Zhang T; Zhao M; He Y; He SH; Wang M; Li YZ; Huang SB; Li Y; Liu J; Cao W; Li TS
Infect Dis Poverty; 2020 Jun; 9(1):75. PubMed ID: 32571409
[TBL] [Abstract][Full Text] [Related]
2. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
3. Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study.
Hermans LE; Carmona S; Nijhuis M; Tempelman HA; Richman DD; Moorhouse M; Grobbee DE; Venter WDF; Wensing AMJ
PLoS Med; 2020 Feb; 17(2):e1003037. PubMed ID: 32097428
[TBL] [Abstract][Full Text] [Related]
4. Impact of low-level viraemia on virological failure among Asian children with perinatally acquired HIV on first-line combination antiretroviral treatment: a multicentre, retrospective cohort study.
Sudjaritruk T; Teeraananchai S; Kariminia A; Lapphra K; Kumarasamy N; Fong MS; Hansudewechakul R; Bunupuradah T; Ly PS; Nallusamy RA; Sohn AH; Sirisanthana V;
J Int AIDS Soc; 2020 Jul; 23(7):e25550. PubMed ID: 32628816
[TBL] [Abstract][Full Text] [Related]
5. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.
Laprise C; de Pokomandy A; Baril JG; Dufresne S; Trottier H
Clin Infect Dis; 2013 Nov; 57(10):1489-96. PubMed ID: 23946221
[TBL] [Abstract][Full Text] [Related]
6. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).
Vandenhende MA; Perrier A; Bonnet F; Lazaro E; Cazanave C; Reigadas S; Chêne G; Morlat P;
Antivir Ther; 2015; 20(6):655-60. PubMed ID: 25735799
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and predictive value of intermittent viremia with combination hiv therapy.
Havlir DV; Bassett R; Levitan D; Gilbert P; Tebas P; Collier AC; Hirsch MS; Ignacio C; Condra J; Günthard HF; Richman DD; Wong JK
JAMA; 2001 Jul; 286(2):171-9. PubMed ID: 11448280
[TBL] [Abstract][Full Text] [Related]
8. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
[TBL] [Abstract][Full Text] [Related]
9. The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.
Dolling DI; Goodall RL; Chirara M; Hakim J; Nkurunziza P; Munderi P; Eram D; Tumukunde D; Spyer MJ; Gilks CF; Kaleebu P; Dunn DT; Pillay D;
BMC Infect Dis; 2017 Feb; 17(1):160. PubMed ID: 28222702
[TBL] [Abstract][Full Text] [Related]
10. Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.
Santoro MM; Di Carlo D; Armenia D; Zaccarelli M; Pinnetti C; Colafigli M; Prati F; Boschi A; Antoni AMD; Lagi F; Sighinolfi L; Gervasoni C; Andreoni M; Antinori A; Mussini C; Perno CF; Borghi V; Sterrantino G
Antivir Ther; 2018; 23(3):249-257. PubMed ID: 28935850
[TBL] [Abstract][Full Text] [Related]
11. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
Meybeck A; Alidjinou EK; Huleux T; Boucher A; Tetart M; Choisy P; Bocket L; Ajana F; Robineau O
AIDS Patient Care STDS; 2020 Feb; 34(2):51-58. PubMed ID: 32049556
[TBL] [Abstract][Full Text] [Related]
12. Impact of Low-level Viremia on Treatment Outcomes During ART - Is it Time to Revise the Definition of Virological Failure?
Poveda E; Crespo M
AIDS Rev; 2018; 20(1):71-72. PubMed ID: 29628513
[TBL] [Abstract][Full Text] [Related]
13. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
Pernas B; Grandal M; Pertega S; Cañizares A; Castro-Iglesias Á; Mena Á; Rodriguez-Osorio I; Tabernilla A; Pedreira JD; Poveda E
J Antimicrob Chemother; 2016 Apr; 71(4):1051-5. PubMed ID: 26702924
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort.
Zhang T; Ding H; An M; Wang X; Tian W; Zhao B; Han X
BMC Infect Dis; 2020 Feb; 20(1):147. PubMed ID: 32066392
[TBL] [Abstract][Full Text] [Related]
15. Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.
Raffi F; Hanf M; Ferry T; Khatchatourian L; Joly V; Pugliese P; Katlama C; Robineau O; Chirouze C; Jacomet C; Delobel P; Poizot-Martin I; Ravaux I; Duvivier C; Gagneux-Brunon A; Rey D; Reynes J; May T; Bani-Sadr F; Hoen B; Morrier M; Cabie A; Allavena C;
J Antimicrob Chemother; 2017 Dec; 72(12):3425-3434. PubMed ID: 28961719
[TBL] [Abstract][Full Text] [Related]
16. Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.
Childs T; Shingadia D; Goodall R; Doerholt K; Lyall H; Duong T; Judd A; Gibb DM; Collins IJ;
Lancet HIV; 2015 Apr; 2(4):e151-8. PubMed ID: 26413561
[TBL] [Abstract][Full Text] [Related]
17. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
[TBL] [Abstract][Full Text] [Related]
18. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.
Parczewski M; Siwak E; Leszczyszyn-Pynka M; Cielniak I; Burkacka E; Pulik P; Witor A; Muller K; Zasik E; Grzeszczuk A; Jankowska M; Lemańska M; Olczak A; Grąbczewska E; Szymczak A; Gąsiorowski J; Szetela B; Bociąga-Jasik M; Skwara P; Witak-Jędra M; Jabłonowska E; Wójcik-Cichy K; Kamerys J; Janczarek M; Krankowska D; Mikuła T; Kozieł K; Bielec D; Stempkowska J; Kocbach A; Błudzin W; Horban A
J Int AIDS Soc; 2017 Jul; 20(1):21847. PubMed ID: 28715160
[TBL] [Abstract][Full Text] [Related]
19. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
Domingo P; Ribera E
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
[TBL] [Abstract][Full Text] [Related]
20. Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
Alvarez-Uria G; Pakam R; Naik PK; Midde M
PLoS One; 2014; 9(9):e108063. PubMed ID: 25232730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
